Phase II sttr development of an intranasal/oral spirulina-based pfcsp malaria vaccine
Ended Project Grant Awarded Last action
- Award ID
- R42AI138623
- Recipient
-
Lumen Bioscience, Inc. UEI E9UJDT3BFUQ5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,893,347
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $4,893,346.94 Federal
- $1,000,000.00 Non-federal
- Place of performance
- Washington, USA
Award details come from USAspending.gov.
Description
- Abstract
- Vaccination represents the single most effective and cost-effective medical intervention devised to date, saving lives and reducing morbidity and disability for billions of humans. Despite the early success of the oral polio vaccine, most vaccines are delivered parenterally, and as such are associated with pain, non-compliance, biohazardous medical waste and the need for trained medical personnel. Moreover, strict requirements for production, transport and storage logistics (the "cold chain") are costly and present substantial logistical challenges. Mucosal (oral, intranasal, etc.) vaccine strategies eliminate or significantly reduce these drawbacks. The potential use of arthrospira platensis (commonly called spirulina) as an oral vaccine delivery platform is highly attractive, given its safety profile, rich nutritional content and wide acceptance as a human food source. Lumen bioscience has developed unique, patented technology to genetically engineer spirulina to express heterologous proteins. Lumen bioscience's spirulina vaccine platform consists of recombinant strains designed to express viral capsid proteins that assemble and form durable high-order complexes commonly called virus-like particles (VLPS). Parenterally-administered VLP-based vaccines have been used in humans for prevention of infections with human papilloma virus, hepatitis B virus, and malaria parasites. Intranasally and orally- administered spirulina-expressed VLPS have been engineered to efficiently express pathogen-derived antigens inserted into the exterior-facing VLP domains. Here, VLPS bearing epitopes derived from plasmodium falciparum circumsporozoite protein (CSP) in spirulina will be administered intranasally and orally to mice and non-human primates. This approach has been shown to induce systemic anti-CSP IGG, which confers protection against sporozoite challenge in mouse models. This project aims to optimize and develop the intranasal/oral spirulina vaccine model as a safe and effective malaria vaccine using mice and non-human primate models to enable a future transition to the clinic.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$31,953 | $0 | |
| Amendment | $925,300 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,000,000 | $0 | |
| Original award | $1,000,000 | $1,000,000 |
Show all 13
Quick answers
Who received award R42AI138623?
R42AI138623 was awarded to Lumen Bioscience, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 17, 2018.
How much is award R42AI138623 worth?
$5,893,347 has been obligated on R42AI138623: $4,893,347 in federal funding and $1,000,000 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award